Life Sciences Partners (LSP Group)
|
Life Sciences Partners Employees in Amsterdam: 11 |
Company Profile
LSP (Life Sciences Partners) is a leading independent European investment firm, providing financing to private and public life-science companies. Since the late 1980s, LSP's management has invested in a large number of highly innovative enterprises, many of which have grown to become leaders of the global life-science industry. For example, LSP was a founding investor in Crucell, DNage, Qiagen, Rhein Biotech and Pharming.
With over EUR 500 million under management and offices in Amsterdam, Munich and Boston, LSP is one of Europe's largest and most experienced specialist life-science investors.
Science and Technologies or Services
Life Sciences Partners (LSP) is one of the largest European venture capital firms, providing private equity capital to early-stage and mid-stage life sciences companies. Based in Amsterdam and Munich, LSP's management has focused for over 20 years on investing in human life sciences. By carefully balancing risks, and by adding value as lead investor and board member of its portfolio companies, LSP's management has achieved returns in the upper decile of the European private equity industry. In total, LSP's management has been responsible for equity investments in over 50 life sciences companies, primarily in therapeutics and platform technologies in Europe. To date, fourteen of these companies have been publicly listed on NASDAQ, EASDAQ, Neuer Markt, Stockholm Stock Exchange, LSE and AEX, and ten have been sold to strategic partners. With a strong management team and an extensive scientific, industry and financial network in place, LSP currently has over EUR 500 million in capital under management.
In addition to the human life sciences, LSP won a $100 million competitive tender to invest in non-medical life sciences. This mandate, called LSP Bioventures, was awarded in 2006 by Syngenta, the $20 billion agricultural company, and is managed by a separate dedicated team in Boston. LSP also has a mandate from ABP, one of the largest pension funds, to invest in public European life-science companies. This activity is managed by a separate team in Amsterdam.
Keywords
- Biotechnology;
- Life Sciences;
- Medical devices;
- BioEnergy;
- Food;
- Nutrician;
- Welness;
- Agriculture,
